A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Inclusion Criteria

• Histologically confirmed stage II through IIIB (N2) NSCLC, that is considered resectable with curative intent, as described in the protocol
• Measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1
• Available formalin-fixed paraffin-embedded (FFPE) tumor sample blocks for submission, as described in the protocol
• Eastern Cooperative Oncology Group Performance Status scale (ECOG PS) of 0 to 1
• Adequate organ and bone marrow function, as described in the protocol General Key

Exclusion Criteria

• Any systemic anti-cancer therapy or radiotherapy for the current tumor, as described in the protocol
• Presence of known oncogenic alterations in epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) in the tumor prior to randomization, as described in the protocol
• Presence of grade≥ 2 peripheral neuropathy
• Another malignancy that is progressing or requires active treatment, as described in the protocol Arm Specific Exclusion Criteria: Arm 1:
• Grade ≥3 hypercalcemia, as defined in the protocol
• Any central nervous system (CNS) pathology that could increase the risk of immune effector cell-associated neurotoxicity syndrome (ICANS), as described in the protocol
• Has marked baseline prolongation of the time from the start of the Q wave to the end of the T wave in electrocardiogram (QT)/corrected QT interval (QTc) interval or risk factors for prolonged QTc, as described in the protocol Note: Other protocol-defined Inclusion/Exclusion criteria apply.